Alzheimer's Disease
FDA grants 510(k) clearance to amyloid imaging tool
The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission tomography-based amyloid imaging to evaluate individuals for Alzheimer’s disease-related pathology.
Putative retinal gliosis may serve as biomarker for preclinical Alzheimer’s disease
Patients with preclinical Alzheimer’s disease had significantly greater putative retinal gliosis compared with controls, according to study results published in Investigative Ophthalmology & Visual Science.
Depressive symptoms linked to amyloid accumulation, suggesting ties to preclinical AD
Increasing depressive symptoms among cognitively unimpaired older adults appeared significantly associated with early amyloid accumulation in brain regions involved in emotional control, according to a study published in JAMA Network Open.
FDA grants fast-track designation to injectable positron emission tomography diagnostic
The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.
Small molecule oligomer antagonist for Alzheimer’s disease boosts brain connectivity
Results of an ongoing clinical trial showed that an oral, small molecule oligomer antagonist used to treat mild to moderate Alzheimer’s disease boosted connectivity between regions of the brain as a promising sign of cognitive improvement.
SGLT2 inhibitors tied to similar dementia risk as dulaglutide in type 2 diabetes
SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.
‘Concerning trends’ in dementia mortality most notable among Black adults, women in US
Mortality data from 1999 to 2020 revealed an upward trend in dementia-related mortality in the United States, especially among Black adults and women, according to a study published in The Primary Care Companion for CNS Disorders.
Alpha Cognition receives notice of allowance for US patent of novel AD drug
A Vancouver-based biopharmaceutical company has secured a notice of allowance, presaging a U.S. patent for a crystalline formulation of a novel acetylcholinesterase inhibitor to treat Alzheimer’s disease.
Aruna Bio secures US patent for exosome-derived neuroinflammation treatment
A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.
Top in cardiology: Low SGLT2 inhibitor prescription rates; workplace stress and AF risk
Most patients who qualified for an SGLT2 inhibitor were not prescribed one, according to an analysis of more than 3 million U.S. adults.